Pathogenesis of the antiphospholipid syndrome: An additional example of the mosaic of autoimmunity

Journal of Autoimmunity

Volumn 30, Issue 1-2, 2008, Pages 99-103

  Meroni, Pier Luigi ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Anti beta2 glycoprotein I antibodies; Antiphospholipid syndrome; Autoimmunity; Innate immunity

Indexed keywords

AUTOANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY;

ADAPTIVE IMMUNITY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNITY; BLOOD CLOT LYSIS; CROSS REACTION; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; INNATE IMMUNITY; MEDIATOR; MOSAICISM; NONHUMAN; PRIORITY JOURNAL; TARGET ORGAN; THROMBOGENICITY;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; AUTOIMMUNITY; BETA 2-GLYCOPROTEIN I; HUMANS; IMMUNITY, ACTIVE; IMMUNITY, NATURAL; THROMBOSIS;

EID: 38049064823     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2007.11.014     Document Type: Article

References (53)

1. Levine J.S., Branch D.W., and Rauch J. The antiphospholipid syndrome. N Engl J Med 346 (2002) 752-763
2. Rose N.R., and Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today 14 (1993) 426-430
3. Meroni P.L., and Riboldi P. Pathogenic mechanisms of antiphospholipid syndrome: a new autoimmune disease. Drug Disc Today: Dis Mech 1 (2004) 309-314
4. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 (2006) 295-306
5. Galli M., Borrelli G., Jacobsen E.M., Marfisi R.M., Finazzi G., Marchioli R., et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood 110 (2007) 1178-1183
6. Vega-Ostertag M.E., and Pierangeli S.S. Mechanisms of aPL-mediated thrombosis: effects of aPL on endothelium and platelets. Curr Rheumatol Rep 9 (2007) 190-197
7. Di Simone N., Meroni P.L., D'Asta M., Di Nicuolo F., D'Alessio M.C., and Caruso A. Pathogenic role of anti-{beta}2-glycoprotein I antibodies on human placenta: functional effects related to implantation and roles of heparin. Hum Reprod Update 13 (2007) 189-196
8. Redecha P., Tilley R., Tencati M., Salmon J.E., Kirchhofer D., Mackman N., et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 110 (2007) 2423-2431
9. Berman J., Girardi G., and Salmon J.E. TNF-α is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 174 (2005) 485-490
10. Martinez de la Torre Y., Buracchi C., Borroni E.M., Dupor J., Bonecchi R., Nebuloni M., et al. Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. Proc Natl Acad Sci U S A 104 (2007) 2319-2324
11. Borghi M.O., Raschi E., Scurati S., Grossi C., Chen P.P., Pierangeli S.S., et al. Effects of Toll-like receptor antagonist and anti-annexin A2 antibodies on binding and activation of decidual cells by anti-β2-glycoprotein I antibodies. Clin Exp Rheumatol 2 (2007) 35 abstract 147
12. Lavazza T., Dipinto A., Borghi M.O., Usuelli V., Bergamaschi A., Zimarino V., et al. Antiphospholipid antibodies and central nervous system involvement: direct autoantibody binding to neuronal cells. Clin Exp Rheumatol 2 (2007) 25 abstract 101
13. Kuwana M. Autoreactive CD4(+) T cells to beta(2)-glycoprotein I in patients with antiphospholipid syndrome. Autoimmun Rev 2 (2003) 192-198
14. Yamaguchi Y., Seta N., Kaburaki J., Kobayashi K., Matsuura E., and Kuwana M. Excessive exposure to anionic surfaces maintains autoantibody response to β2-glycoprotein I in patients with antiphospholipid syndrome. First Edition Paper, prepublished online August 28. Blood 110 (2007) 4312-4318
15. Fischetti F., Durigutto P., Pellis V., Debeus A., Macor P., Bulla R., et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 106 (2005) 2340-2346
16. Pierangeli S.S., Girardi G., Vega-Ostertag M., Liu X., Espinola R.G., and Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 52 (2005) 2120-2124
17. Munakata Y., Saito T., Matsuda K., Seino J., Shibata S., and Sasaki T. Detection of complement-fixing antiphospholipid antibodies in association with thrombosis. Thromb Haemost 83 (2000) 728-731
18. Shamonki J.M., Salmon J.E., Hyjek E., and Baergen R.N. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 196 (2007) 167.e1-167.e5
19. Cavazzana I., Nebuloni M., Cetin I., Acaia B., Saino S., Borghi M.O., et al. Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process?. J Autoimmun 28 (2007) 160-164
20. Chaouat G. The Th1/Th2 paradigm: still important in pregnancy?. Semin Immunopathol 29 (2007) 95-113
21. Shoenfeld Y., Blank M., Cervera R., Font J., Raschi E., and Meroni P.L. Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis 65 (2006) 2-6
22. Raschi E., Testoni C., Bosisio D., Borghi M.O., Koike T., Mantovani A., et al. Role of the MyD88 transduction signalling pathway in endothelial activation by antiphospholipid antibodies. Blood 101 (2003) 3495-3500
23. Pierangeli S.S., Vega-Ostertag M.E., Raschi E., Liu X., Romay-Penabad Z., De Micheli V., et al. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis 66 (2007) 1327-1333
24. Schröder N.W.J., and Schumann R.R. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet 5 (2005) 156-164
25. Atsumi T., and Amengual O. Genetics of antiphospholipid syndrome in Hughes syndrome. In: Khamastha M.A. (Ed). Hughes syndrome: antiphospholipid syndrome (2006), Springer-Verlag, London 521
26. Jiménez S, Tàssies D, Espinosa G, García-Criado A, Plaza J, Monteagudo J, et al. Platelet glycoprotein Ib-alfa, Ia/IIa and IIb/IIIa polymorfisms and vascular arterial disease in patients with the antiphospholipid syndrome or with systemic lupus erythematosus. Ann Rheum Dis, in press.
27. Blank M., Krause I., and Shoenfeld Y. Antiphospholipid syndrome - experimental models: insight into etiology, pathogenesis, and treatment in Hughes syndrome. In: Khamastha M.A. (Ed). Hughes syndrome: antiphospholipid syndrome (2006), Springer-Verlag, London 375
28. Tincani A., Gilburd B., Abu-Shakra M., Blank M., Allegri F., Ottaviani R., et al. Immunization of naive BALB/c mice with human beta2-glycoprotein I breaks tolerance to the murine molecule. Arthritis Rheum 46 (2002) 1399-1404
29. Belizna C.C., Richard V., Thuillez C., Lévesque H., and Shoenfeld Y. Insights into atherosclerosis therapy in antiphospholipid syndrome. Autoimmun Rev 7 (2007) 46-51
30. Kajiwara T., Yasuda T., and Matsuura E. Intracellular trafficking of beta2-glycoprotein I complexes with lipid vesicles in macrophages: implications on the development of antiphospholipid syndrome. J Autoimmun 29 (2007) 164-173
31. Soltész P., Szekanecz Z., Kiss E., and Shoenfeld Y. Cardiac manifestations in antiphospholipid syndrome. Autoimmun Rev 6 (2007) 379-386
32. Koike T., Bohgaki M., Amengual O., and Atsumi T. Antiphospholipid antibodies: lessons from the bench. J Autoimmun 28 (2007) 129-133
33. Kiss E., Soltesz P., Der H., Kocsis Z., Tarr T., Bhattoa H., et al. Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients. J Autoimmun 27 (2006) 211-217
34. Languren M., Becerril B., Cabral A.R., Fernández-Altuna LE., Pascual V., Hernandez-Ramírez DF., et al. Characterization of monoclonal anti-beta2-glycoprotein-I and anti-prothrombin antibody fragments generated by phage display from a patient with primary antiphospholipid syndrome. J Autoimmun 26 (2006) 57-65
35. Ambrozic A., Cucnik S., Tomsic N., Urbanija J., Lokar M., Babnik B., et al. Interaction of giant phospholipids vesicles containing cardiolipin and cholesterol with beta2-glycoprotein-I and anti-beta2-glycoprotein-I antibodies. Autoimmun Rev 6 (2006) 10-15
36. McIntyre J.A., and Wagenknecht D.R. Anti-phosphatidylethanolamine (aPE) antibodies: a survey. J Autoimmun 15 2 (2000) 185-193
37. Esposito G., Tamby M.C., Chanseaud Y., Servettaz A., Guillevin L., and Mouthon L. Anti-annexin V antibodies: are they prothrombotic?. Autoimmun Rev 4 (2005) 55-60
38. Bagnasco M., Grassia L., and Pesce G. The management of the patient with unexpected autoantibody positivity. Autoimmun Rev 6 (2007) 347-353
39. Muscal E., and Myones B.L. The role of autoantibodies in pediatric neuropsychiatric systemic lupus erythematosus. Autoimmun Rev 6 (2007) 215-217
40. Borchers A.T., Aoki C.A., Naguwa S.M., Keen CL., Shoenfeld Y., and Gershwin ME. Neuropsychiatric features of systemic lupus erythematosus. Autoimmun Rev 4 (2005) 329-344
41. Wu R., Shen G., Morris R., Patnaik M., and Peter JB. Elevated autoantibodies against oxidized palmitoyl arachidonoyl phosphocholine in patients with hypertension and myocardial infarction. J Autoimmun 24 (2005) 353-360
42. Abraham M., Karni A., Dembinsky A., Miller A., Gandhi R., Anderson D., et al. In vitro induction of regulatory T cells by anti-CD3 antibody in humans. J Autoimmun 30 (2008) 21-28
43. Andreoli L., Pregnolato F., Burlingame R., Allegri F., Rizzini S., Fanelli V., et al. Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity. J Autoimmun 30 (2008) 51-57
44. Binard A., Le Pottier L., Saraux A., Devauchelle-Pensec V., Pers J.-O., and Youinou P. Does the BAFF dysregulation play a major role in the pathogenesis of systemic lupus erythematosus?. J Autoimmun 30 (2008) 63-67
45. Jacobson E., Huber A., and Tomer Y. The HLA gene complex in thyroid autoimmunity: from epidemiology to etiology. J Autoimmun 30 (2008) 58-62
46. Kallenberg C. Pathogenesis of PR3-ANCA associated vasculitis. J Autoimmun 30 (2008) 29-36
47. Mackay I., Leskovek N., and Rose N. Cell damage and autoimmunity: a critical appraisal. J Autoimmun 30 (2008) 5-11
48. Nakanishi Y., Tsuneyama K., Fujimoto M., Thucydides L., Nomoto K., An J.-L., et al. Monosodium glutamate (MSG): a villain and promoter of liver inflammation and dysplasia. J Autoimmun 30 (2008) 42-50
49. Poletaev A., Stepanyuk V., and Gershwin M. Integrating immunity: the immunculus and self reactivity. J Autoimmun 30 (2008) 68-73
50. Praprotnik S., Snezna S.-S., Tomsic M., and Shoenfeld Y. The curiously suspicious: infectious disease may ameliorate an ongoing autoimmune destruction in systemic lupus erythematosus patients. J Autoimmun 30 (2008) 37-41
51. Recalcati S., Invernizzi P., Arosio P., and Cairo G. New functions for an iron storage protein: the role of ferritin in immunity and autoimmunity. J Autoimmun 30 (2008) 84-89
52. Sanchez-Pernaute O., Ospelt C., Neidhart M., and Gay S. Epigenetic clues to rheumatoid arthritis. J Autoimmun 30 (2008) 12-20
53. Boren E, Gershwin M. Review of progressive multifocal leukoencephalopathy (PML) and its emergence in rheumatic diseases. J Autoimmun, in press.